Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

NCT00468286 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Degarelix
DRUG: Degarelix

Sponsor

Ferring Pharmaceuticals